Xencor, Inc.
XNCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeXencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. With a market capitalization of $1.30B, it sits in small-cap territory. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Market Cap
$1.30B
Beta
0.86
P/E (TTM)
—
P/E (Fwd)
-4.92
EPS (TTM)
$-2.29
EPS (Fwd)
$-3.55
ROE
-29.8%
ROA
-16.2%
Cash
$445.0M
Total Debt
$175.2M
Free CF
-$76.9M
52W Change
94.8%
Annual Financials
Cash vs Debt
With $445.0M in cash and $175.2M in debt, XNCR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$76.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -29.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $275.1M to $125.6M.
With cash comfortably exceeding debt, XNCR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing XNCR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.